Randomized Clinical Trials in Gastrointestinal Stromal Tumors

Surgical Oncology Clinics of North America

Volumn 19, Issue 1, 2010, Pages 101-113

  Learn, Peter A ^a   Sicklick, Jason K ^a   DeMatteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Disease free survival; Gastrointestinal stromal tumor; Recurrence free survival

Indexed keywords

DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; PLACEBO; SUNITINIB; TEMOZOLOMIDE;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DERMATITIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HUMAN; HYPERGLYCEMIA; LONG TERM CARE; LOW DRUG DOSE; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHORT COURSE THERAPY; SKIN DISCOLORATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

GASTROINTESTINAL STROMAL TUMORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70449380266     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2009.09.004     Document Type: Review

References (20)

1. Katz S.C., and DeMatteo R.P. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol 97 (2008) 350
2. Dematteo R.P., Heinrich M.C., El-Rifai W.M., et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33 (2002) 466
3. Edmonson J.H., Marks R.S., Buckner J.C., et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 20 (2002) 605
4. Trent J.C., Beach J., Burgess M.A., et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 98 (2003) 2693
5. Von Burton G., Rankin C., Zalupski M.M., et al. Phase II trial of gemcitabine as first-line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 29 (2006) 59
6. Blair S.C., Zalupski M.M., and Baker L.H. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol 17 (1994) 480
7. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127
8. Nilsson B., Nilsson O., and Ahlman H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib-and then?. Expert Opin Investig Drugs 18 (2009) 457
9. Kingham T.P., and DeMatteo R.P. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am 89 (2009) 217
10. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052
11. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472
12. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 (2008) 620
13. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26 (2008) 626
14. Zalcberg J.R., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 (2005) 1751
15. Van Glabbeke M., Owzar K., Rankin C., et al. Comparisonof two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): a meta-analysis based on 1,640 patients [supplement]. J Clin Oncol 25 (2007) S546
16. Blay J.Y., Le Cesne A., Ray-Coquard I., et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25 (2007) 1107
17. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. [see comment]. Lancet 368 (2006) 1329
18. Dematteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373 (2009) 1097
19. Eisenberg B.L., Harris J., Blanke C.D., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99 (2009) 42
20. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 25 (2007) 1760